Tuning the performance of CAR T cell immunotherapies

BACKGROUND: Simultaneous advances in gene editing, T cell engineering and biotechnology currently provide an opportunity for rapid progress in medicine. The approval of chimeric antigen receptor (CAR) T cell therapies by the US Food and Drug Administration (FDA) and the European Commission have gene...

Descripción completa

Detalles Bibliográficos
Autores principales: Richardson, Noah H., Luttrell, Jordan B., Bryant, Jonathan S., Chamberlain, Damian, Khawaja, Saleem, Neeli, Indira, Radic, Marko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884819/
https://www.ncbi.nlm.nih.gov/pubmed/31783836
http://dx.doi.org/10.1186/s12896-019-0576-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884819/
https://www.ncbi.nlm.nih.gov/pubmed/31783836
http://dx.doi.org/10.1186/s12896-019-0576-9

Ejemplares similares